Similar articles for PMID: 17479288

Year	Number of Results
1961	1
1976	1
1991	1
1992	2
1993	2
1994	2
1995	2
1997	1
1998	4
2000	4
2001	8
2002	6
2003	6
2004	6
2005	8
2006	5
2007	7
2008	3
2009	2
2010	7
2011	5
2012	3
2013	5
2014	1
2015	2
2016	4
2017	5
2018	3
2019	4
2020	2
2021	3
2022	4
2024	0

1

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.

Simon T, Längler A, Harnischmacher U, Frühwald MC, Jorch N, Claviez A, Berthold F, Hero B. Simon T, et al. J Cancer Res Clin Oncol. 2007 Sep;133(9):653-61. doi: 10.1007/s00432-007-0216-y. Epub 2007 May 4. J Cancer Res Clin Oncol. 2007. PMID: 17479288 Clinical Trial.

2

Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial.

Simon T, Längler A, Berthold F, Klingebiel T, Hero B. Simon T, et al. J Pediatr Hematol Oncol. 2007 Feb;29(2):101-6. doi: 10.1097/MPH.0b013e3180320b48. J Pediatr Hematol Oncol. 2007. PMID: 17279006 Clinical Trial.

3

Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.

Rujkijyanont P, Photia A, Traivaree C, Monsereenusorn C, Anurathapan U, Seksarn P, Sosothikul D, Techavichit P, Sanpakit K, Phuakpet K, Wiangnon S, Chotsampancharoen T, Chainansamit SO, Kanjanapongkul S, Meekaewkunchorn A, Hongeng S. Rujkijyanont P, et al. BMC Cancer. 2019 Oct 16;19(1):961. doi: 10.1186/s12885-019-6186-z. BMC Cancer. 2019. PMID: 31619207 Free PMC article.

4

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H. Di Giannatale A, et al. Eur J Cancer. 2014 Jan;50(1):170-7. doi: 10.1016/j.ejca.2013.08.012. Epub 2013 Sep 7. Eur J Cancer. 2014. PMID: 24021349 Clinical Trial.

5

Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.

Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L, Cozza R, Fidani P, Deb G, De Laurentis C, Inserra A, Dominici C. Donfrancesco A, et al. Acta Paediatr Suppl. 2004 May;93(445):6-11. doi: 10.1111/j.1651-2227.2004.tb03048.x. Acta Paediatr Suppl. 2004. PMID: 15176712 Clinical Trial.

6

Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.

Feng C, Tang S, Wang J, Liu Y, Yang G. Feng C, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2013 Aug;33(8):1107-10. Nan Fang Yi Ke Da Xue Xue Bao. 2013. PMID: 23996746

7

Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.

Donfrancesco A, De Ioris MA, McDowell HP, De Pasquale MD, Ilari I, Jenkner A, Castellano A, Cialfi S, De Laurentis C, Dominici C. Donfrancesco A, et al. Pediatr Blood Cancer. 2010 Jan;54(1):55-61. doi: 10.1002/pbc.22219. Pediatr Blood Cancer. 2010. PMID: 19821523

8

Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.

De Ioris MA, Castellano A, Ilari I, Garganese MC, Natali G, Inserra A, De Vito R, Ravà L, De Pasquale MD, Locatelli F, Donfrancesco A, Jenkner A. De Ioris MA, et al. Eur J Cancer. 2011 Mar;47(4):572-8. doi: 10.1016/j.ejca.2010.10.023. Epub 2010 Nov 26. Eur J Cancer. 2011. PMID: 21112775

9

Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).

Mora J, Cruz O, Lavarino C, Rios J, Vancells M, Parareda A, Salvador H, Suñol M, Carrasco R, Guillen A, Mañé S, de Torres C. Mora J, et al. Clin Transl Oncol. 2015 Jul;17(7):521-9. doi: 10.1007/s12094-014-1273-8. Epub 2015 Jan 17. Clin Transl Oncol. 2015. PMID: 25596034

10

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, Hayashi R, Vietti TJ; Pediatric Oncology Group. Saylors RL 3rd, et al. J Clin Oncol. 2001 Aug 1;19(15):3463-9. doi: 10.1200/JCO.2001.19.15.3463. J Clin Oncol. 2001. PMID: 11481351 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

109 results

Results by year